A share price of Fractyl Health Inc [GUTS] is currently trading at $0.98, up 0.71%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GUTS shares have lost -47.39% over the last week, with a monthly amount drifted -37.33%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley started tracking the stock with Overweight rating on February 27, 2024, and set its price target to $18. On February 27, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $26 on the stock.
Fractyl Health Inc experienced fluctuations in its stock price throughout the past year between $0.82 and $3.72. Fractyl Health Inc [NASDAQ: GUTS] shares were valued at $0.98 at the most recent close of the market.
Analyzing the GUTS fundamentals
Trailing Twelve Months sales for Fractyl Health Inc [NASDAQ:GUTS] were 0.06M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at -3.23% with Operating Profit Margin at -1612.47%, Pretax Profit Margin comes in at -1485.12%, and Net Profit Margin reading is -1485.12%. To continue investigating profitability, this company’s Return on Assets is posted at -1.07, Equity is -2.29 and Total Capital is -1.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 9.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9493 points at the first support level, and at 0.9146 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0193, and for the 2nd resistance point, it is at 1.0546.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Fractyl Health Inc [NASDAQ:GUTS] is 2.50. As well, the Quick Ratio is 2.50, while the Cash Ratio is 2.24. Considering the valuation of this stock, the price to sales ratio is 1115.49, the price to book ratio is 7.55.
Transactions by insiders
Recent insider trading involved Royan Ajay, Director, that happened on Mar 14 ’25 when 17901.0 shares were purchased. Director, Barnes Kelly Ann completed a deal on Mar 14 ’25 to buy 31000.0 shares. Meanwhile, Director SCHULMAN AMY W bought 8550.0 shares on Mar 13 ’25.
